Positive News SentimentPositive NewsNASDAQ:AVBP ArriVent BioPharma (AVBP) Stock Price, News & Analysis $27.97 -0.60 (-2.10%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$28.04 +0.07 (+0.25%) As of 05:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About ArriVent BioPharma Stock (NASDAQ:AVBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ArriVent BioPharma alerts:Sign Up Key Stats Today's Range$27.70▼$28.7550-Day Range$27.97▼$33.6952-Week Range$17.00▼$35.83Volume337,267 shsAverage Volume447,585 shsMarket Capitalization$1.38 billionP/E RatioN/ADividend YieldN/APrice Target$44.86Consensus RatingModerate Buy Company Overview ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with genetically defined cancers. The company’s strategy is to identify promising therapies that have been developed or clinically validated in other markets and advance them through global development programs. ArriVent’s lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The company is evaluating furmonertinib as a potential treatment for patients with EGFR-mutated non-small cell lung cancer, including tumors with EGFR exon 20 insertion mutations and other EGFR alterations. ArriVent obtained exclusive development and commercialization rights for furmonertinib outside China through a collaboration with Allist Pharmaceuticals. The company is headquartered in the United States and is conducting development activities intended to support potential commercialization in the U.S. and other international markets. ArriVent’s pipeline and programs remain focused primarily on targeted cancer therapies.AI Generated. May Contain Errors. Read More ArriVent BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreAVBP MarketRank™: ArriVent BioPharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 554th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArriVent BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialArriVent BioPharma has a consensus price target of $44.86, representing about 60.4% upside from its current price of $27.97.Amount of Analyst CoverageArriVent BioPharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ArriVent BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ArriVent BioPharma are expected to grow in the coming year, from ($4.01) to ($3.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ArriVent BioPharma is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ArriVent BioPharma is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArriVent BioPharma has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ArriVent BioPharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.28% of the float of ArriVent BioPharma has been sold short.Short Interest Ratio / Days to CoverArriVent BioPharma has a short interest ratio ("days to cover") of 20.43, which indicates bearish sentiment.Change versus previous monthShort interest in ArriVent BioPharma has recently increased by 5.64%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArriVent BioPharma does not currently pay a dividend.Dividend GrowthArriVent BioPharma does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentArriVent BioPharma has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for ArriVent BioPharma this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for AVBP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders8.58% of the stock of ArriVent BioPharma is held by insiders.Percentage Held by Institutions9.48% of the stock of ArriVent BioPharma is held by institutions.Read more about ArriVent BioPharma's insider trading history. Receive AVBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVBP Stock News HeadlinesArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer StudySeptember 3, 2026 | tipranks.comArriVent inks China partnership for ARR-002 developmentAugust 12, 2026 | tipranks.com$20,000 gold before year end?President Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story.September 16 at 1:00 AM | Stansberry Research (Ad)ArriVent BioPharma Reports Second Quarter 2026 Financial ResultsAugust 12, 2026 | globenewswire.comArriVent BioPharma, Inc. (AVBP)July 16, 2026 | finance.yahoo.comArriVent BioPharma, Inc. (AVBP) Receives a Buy from OppenheimerJuly 13, 2026 | theglobeandmail.comH.C. Wainwright Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)July 12, 2026 | theglobeandmail.comArriVent BioPharma Stock Short Interest Report | NASDAQ:AVBP | BenzingaJune 30, 2026 | benzinga.comSee More Headlines AVBP Stock Analysis - Frequently Asked Questions How have AVBP shares performed this year? ArriVent BioPharma's stock was trading at $20.12 on January 1st, 2026. Since then, AVBP stock has increased by 39.0% and is now trading at $27.97. How were ArriVent BioPharma's earnings last quarter? ArriVent BioPharma, Inc. (NASDAQ:AVBP) issued its earnings results on Wednesday, August, 12th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by $0.06. When did ArriVent BioPharma IPO? ArriVent BioPharma (AVBP) raised $175 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 9,722,222 shares at $17.00-$19.00 per share. Who are ArriVent BioPharma's major shareholders? Top institutional investors of ArriVent BioPharma include Montanova Capital LLC (9.16%), Hhlr Advisors LTD. (8.44%), BlackRock Inc. (6.98%) and General Catalyst Group Management LLC (3.21%). Insiders that own company stock include Hillhouse Investment Managemen and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of ArriVent BioPharma? Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ArriVent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ArriVent BioPharma investors own include CRISPR Therapeutics (CRSP), Opendoor Technologies (OPEN), Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/12/2026Today9/16/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 AVBP's financial health is in the Green zone, according to TradeSmith. AVBP has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AVBP Previous SymbolNASDAQ:AVBP CIK1868279 Webwww.arrivent.com Phone628-277-4836FaxN/AEmployees77Year FoundedN/APrice Target and Rating Average Price Target for ArriVent BioPharma$44.86 High Price Target$50.00 Low Price Target$40.00 Potential Upside/Downside+60.4%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$166.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-50.26% Return on Assets-46.66% Debt Debt-to-Equity RatioN/A Current Ratio14.16 Quick Ratio14.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.44 per share Price / Book3.76Miscellaneous Outstanding Shares49,310,000Free Float45,077,000Market Cap$1.38 billion OptionableN/A Beta1.35 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:AVBP) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVBP Stock Alerts